First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis

Ren, Zheng-Ju; Cao, Deliang; Zhang, Qin; Ren, Pengwei; Liu, Liang-Ren; Wang, Qiang; Wei, Wuran; Dong, Qiang

doi:10.1186/s12885-019-6055-9

Cited by 34 publications

(25 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The signi cance of our review was to provide suggestions on screening and early detection of second primary cancer after pelvic RT. Accumulated evidence showed that patients with cancer history increase the risk of second primary cancer (19), we suppose that radiotherapy would exacerbate this situation. We conducted a systematic review and meta-analysis to demonstrate the relationship between the exposure of pelvic radiation and developing secondary bladder cancer.…”

Section: Introductionmentioning

confidence: 93%

Whether pelvic radiotherapy increased the risk of secondary bladder cancer? A systematic review and meta-analysis

Dou¹,

Ren²,

Hu³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background The question whether pelvic radiotherapy increases the risk of secondary bladder cancer remains unclear. In this review, we aimed to demonstrate the relationship between exposure to radiation therapy for pelvic malignancies and subsequent second primary bladder cancer risk. Methods We systematically searched Medline, Embase and Web of Science for all associated studies concerning secondary bladder cancer risk and radiotherapy for primary pelvic cancers up to 15 th December 2019. We extracted related study characteristics and outcomes. Risk of bias was assessed by the Newcastle-Ottawa Scale. Outcomes were synthesized with random effect models and Manhtel-Haenszel weighting. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-analysis of Observational studies in Epidemiology (MOOSE) guidelines were used for reporting this systematic review and meta-analysis. We use GRADE system to assess the quality of main outcome. Results We identified 3958 references after literature searching and eventually 19 studies were selected for meta-analysis. Most studies were cohort studies with moderate risk of bias. Compared with patients treated without radiotherapy, our results showed an increased risk of secondary bladder cancer after radiotherapy for pelvic malignancies (RR 1.75,95% Confidence Interval [CI] 1.50-2.05) with moderate quality of evidence. Similar results were also found in organ-specific analysis of radiation therapy for testicular cancer(RR 2.25,95% CI 1.34-3.78),uterine cancer(RR 2.52,95%CI 1.12-5.67) and prostate cancer(RR 1.64 95%CI 1.39-1.93).Although a varied definitions of latency periods used in different studies, the results showed a consistently increased risk of bladder cancer in all analyzed latency periods, and lag time over 10 years ranked as the highest relative risk(RR 2.98,95%CI 1.88-4.71). When compared with no radiotherapy, EBRT and Any RT significantly increased the risk of second primary bladder cancer (RR 2.08,95%CI 1.67-2.61 and RR 1.77,95%CI 1.49-2.10), but not for BT group (RR 1.58,95%CI 0.98-2.55). Conclusion In conclusion, pelvic radiotherapy was associated with higher relative risk of secondary bladder cancer compared with those without radiotherapy. These findings may help outpatient counseling and early detection of secondary cancer after diagnosis and treatment of first primary cancer. Keywords: Secondary Bladder cancer, Pelvic malignancies, Radiotherapy, Meta-analysis

show abstract

Section: Introductionmentioning

confidence: 93%

Whether pelvic radiotherapy increased the risk of secondary bladder cancer? A systematic review and meta-analysis

Dou¹,

Ren²,

Hu³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is well known that BRCA genes are considered as the principal biomarkers for the genetic study of hereditary breast and ovarian cancers [ 27 ]; however, several authors have also reported an association in patients affected with HPCa, which is part of HBOC syndrome [ 8 , 15 , 28 ]. BRCA1 and BRCA2 are tumor suppressor genes, localized on chromosomes 17 and 13, respectively, involved in repairing DNA double strand breaks by the conservative approach of homologous recombination (HR) [ 29 ].…”

Section: Genes Involved In the Predisposition To Hereditary Prostamentioning

confidence: 99%

“…BRCA1 and BRCA2 are tumor suppressor genes, localized on chromosomes 17 and 13, respectively, involved in repairing DNA double strand breaks by the conservative approach of homologous recombination (HR) [ 29 ]. The germline BRCA1 mutations increase the risk of HPCa by 3.8-fold in men aged <65 years, and germline BRCA2 mutations by 8.6-fold [ 8 ]. In a study performed on a cohort of 2019 HPCa patients, 0.9% germline mutations in BRCA1 and 3% in BRCA2 were observed [ 30 ].…”

Section: Genes Involved In the Predisposition To Hereditary Prostamentioning

confidence: 99%

“…Family history of PCa, hereditary breast and ovarian cancer (HBOC) syndrome and Lynch syndrome (LS) are among the most important risk factors compared to age, race, ethnicity and environmental factors for the development of PCa [ 5 , 6 , 7 , 8 , 9 ] and this risk is estimated at 40%−50 % [ 3 ]. Men with a brother or father diagnosed with prostate cancer have a two- to four-fold greater risk of developing PCa [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention

Vietri

Goletti

Caliendo

et al. 2021

IJMS

102

View full text Add to dashboard Cite

Prostate cancer (PCa) is globally the second most diagnosed cancer type and the most common cause of cancer-related deaths in men. Family history of PCa, hereditary breast and ovarian cancer (HBOC) and Lynch syndromes (LS), are among the most important risk factors compared to age, race, ethnicity and environmental factors for PCa development. Hereditary prostate cancer (HPCa) has the highest heritability of any major cancer in men. The proportion of PCa attributable to hereditary factors has been estimated in the range of 5–15%. To date, the genes more consistently associated to HPCa susceptibility include mismatch repair (MMR) genes (MLH1, MSH2, MSH6, and PMS2) and homologous recombination genes (BRCA1/2, ATM, PALB2, CHEK2). Additional genes are also recommended to be integrated into specific research, including HOXB13, BRP1 and NSB1. Importantly, BRCA1/BRCA2 and ATM mutated patients potentially benefit from Poly (ADP-ribose) polymerase PARP inhibitors, through a mechanism of synthetic lethality, causing selective tumor cell cytotoxicity in cell lines. Moreover, the detection of germline alterations in MMR genes has therapeutic implications, as it may help to predict immunotherapy benefits. Here, we discuss the current knowledge of the genetic basis for inherited predisposition to PCa, the potential target therapy, and the role of active surveillance as a management strategy for patients with low-risk PCa. Finally, the current PCa guideline recommendations are reviewed.

show abstract

“…Recent evidence suggests a link between prostate cancer and BRCA2 gene mutations, with an increased relative risk of between 2.5–8.6 and more aggressive disease observed in mutation carriers 10 . BRCA genes are the most well‐known genes linked to breast cancer risk; a recent systematic review has suggested that having a first‐degree female relative with breast cancer may increase an individual's risk of prostate cancer by 18% 11 . As such, it is imperative to ask about family history during any consultation with men wishing to know their risk of having a significant prostate cancer.…”

Section: Risk Factors For Prostate Cancermentioning

confidence: 99%